1-5 of 5
Jonathan VanDyke
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Defining Extrinsic Survival Pathways in CML Progenitor Cells.

Ryan Mackenzie, Jennifer Snead, PhD, Jonathan VanDyke, Michael Deininger, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 941.
https://doi.org/10.1182/blood.V114.22.941.941
Published: 2009
Journal Articles

Effects of CYT387, a Potent Novel JAK2 Inhibitor on JAK2-V617F Induced MPD

Thomas G.P. Bumm, Jeffrey W Tyner, PhD, Jutta Deininger, Marc Loriaux, Jonathan VanDyke, Brian J. Druker, Christopher J Burns, Emmanuelle Fantino3, Michael W.N. Deininger, MD
Journal: Blood
Blood (2008) 112 (11): 856.
https://doi.org/10.1182/blood.V112.11.856.856
Published: 2008
Journal Articles

Absence of SKP2 expression attenuates BCR-ABL–induced myeloproliferative disease

Anupriya Agarwal, Thomas G. P. Bumm, Amie S. Corbin, Thomas O'Hare, Marc Loriaux, Jonathan VanDyke, Stephanie G. Willis, Jutta Deininger, Keiichi I. Nakayama, Brian J. Druker, Michael W. Deininger
Journal: Blood
Blood (2008) 112 (5): 1960–1970.
https://doi.org/10.1182/blood-2007-09-113860
Published: 2008
Includes: Supplemental data
Journal Articles

Chromosomal Abnormalities in the Early Stem Cell Population of CML Patients in Complete Cytogenetic Remission.

Thomas G.P. Bumm, MD, Amy Hanlon Newell, PhD, Jay Oost, Jonathan VanDyke, Susan B. Olson, PhD, Brian J. Druker, MD, Michael W.N. Deininger, MD, PhD
Journal: Blood
Blood (2007) 110 (11): 36.
https://doi.org/10.1182/blood.V110.11.36.36
Published: 2007
Journal Articles

TNF-alpha Plays a Crucial Role in the JAK2-V617F Induced Myeloproliferative Disorder.

Thomas G.P. Bumm, MD, Jonathan VanDyke, Marc Loriaux, MD, PhD, Carolyn Gendron, Lisa G. Wood, PhD, RN, Brian J. Druker, MD, Michael W.N. Deininger, MD, PhD
Journal: Blood
Blood (2007) 110 (11): 675.
https://doi.org/10.1182/blood.V110.11.675.675
Published: 2007